Cellnovo Group announced an important milestone in the EU-funded PEPPER Project with the launch of a first clinical study to test a personalised decision-support solution based on artificial intelligence for people with type 1 diabetes. It is the first project to leverage Cellnovo’s recently CE-marked Bluetooth® and Android™-enabled system as the central platform for multiple connected devices. PEPPER, which stands for Patient Empowerment through Predictive PERsonalised decision support, aims to develop innovative tools to help people with diabetes who must make complex calculations to determine the correct insulin dose they need to administer. This requires them to test glucose levels, factor in the amount of carbohydrates consumed, and account for the impact of a myriad factors including physical activity, stress, and illness, among others. PEPPER’s objective is to go beyond existing tools by offering a personalised decision-making support to simplify insulin dosage calculation. At the heart of the solution are two algorithms processing large amounts of data collected in real time via wearable devices like activity bands and continuous glucose monitors. The first algorithm relies on artificial intelligence to make a personalised recommendation for a dose of insulin, while the second algorithm is a safety system based on glucose level prediction to alert patients to the risk of hyper- and hypo-glycemia, and automatically suspend the insulin pump when necessary. The 4-month clinical study will include 15 patients in centres in London (UK) and Girona (Spain). The recently CE-marked next-generation Cellnovo System, the industry’s first Bluetooth® and Android™-enabled micro-pump for insulin delivery, will serve as the central platform of the PEPPER solution. The system will collect data from multiple connected devices, send them in real time to secure servers to inform the decision support, and display a personal insulin dose recommendation based on the analysis of the individual’s data.